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Cancer is a group of diseases involving abnormal 
cell growth with the potential to invade or spread to 
other sections of the body (1). Cancer is one of the 
main causes of mortality worldwide and 
demonstrates a serious health problem (2).  By 2050, 
according to the World Health Organization (WHO), 
 During the past decade vesicles as a tool to improve drug delivery, 
has created a lot of interest amongst the scientist working in the area 
of drug delivery systems. Based on their biodegradable, 
biocompatible and nonimmunogenic structure, niosomes are 
promising drug carriers that are formed by self-assembly of 
nonionic surfactants and cholesterol in an aqueous phase. Curcumin 
(Cur),  a natural polyphenol found in Curcuma longa, has been 
utilized in multiple medicinal areas from antibiotic to antitumor 
treatment. However, the chemical structure of curcumin results in 
poor stability, low solubility and rapid degradation in vivo, limiting 
its clinical utilization. To address these problems, we have prepared 
a niosome system composed of nonionic surfactants 
polyoxyethylene sorbitan monostearate and cholesterol by thin film 
hydration method. The niosomal curcumin was evaluated for anti-
cancer efficacy in prostate cancer cell line (PC-3) by MTT assay. 
Cur was encapsulated in the niosomes with a high entrapment 
efficiency of 98.4 ± 0.4%. Average particle size was found to be 
127.5 ± 1.2 nm. Niosomal curcumin (Nio -Cur)  exhibited enhanced 
cytotoxic activity against PC-3 cells compared with free Cur. These 
results demonstrated that the Nio -Cur system is a promising 
strategy for the delivery of Cur and prostate cancer therapy. 
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it is anticipated that 17.5 million cancer deaths and 
27 million new cancer cases will happen annually 
(3). Many cancers can be prevented by not 
drinking too much alcohol, maintaining a healthy 
weight, eating plenty of vegetables, fruits and 
whole grains, vaccination against certain 
infectious diseases, not eating too much processed 
and red meat, not smoking and avoiding too much 
sunlight exposure (4).  
The prostate is below the bladder and in front of the 
rectum. The size of the prostate changes with age. 
In younger men, it is about the size of a walnut, but 
it can be much larger in older men (5). Prostate 
cancer is the development of cancer in the prostate. 
Prostate cancers are slow growing; however, some 
grow relatively quickly. The cancer cells may 
spread from the prostate to other region of the 
body, particularly the bones and lymph nodes. It 
may initially cause no symptoms. In later stages it 
can lead to difficulty urinating, blood in the urine, 
or pain in the pelvis, back or when urinating (6,7). 
Older age, a family history of the disease, and race 
are factors that increase the risk of prostate cancer 
(8, 9). Prostate-specific antigen (PSA), blood test 
and a digital rectal exam (DRE) and finally a 
prostate biopsy are the main methods of diagnosis 
of prostate cancer (7). Prostate cancer is the most 
frequently diagnosed non-cutaneous neoplasm in 
and the second leading cause of cancer-related 
mortality in men (10,11). Prostate cancer is 
frequently diagnosed in men between 45 and 89 
years of age (12).  It is a major cause of morbidity 
and mortality in Iran. Prostate cancer is becoming 
an increasingly important public health problem,  
particularly  in  countries  with  trends  toward  an  
aging  population (13).  
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Routine screening, early diagnosis, newer treatment 
options and the possibility of cure have increased 
prostate cancer survivorship impressively. There is 
a huge difference in the rate of incidence of prostate 
cancer between Western (120 per 100,000 in 
Northern America) and East Asian countries (less 
than 10 per 100,000 in Asia). Current therapies 
(radical prostatectomy, chemotherapy, local 
radiotherapy or hormonotherapy), although 
successful to treat localized,   androgen-dependent 
prostate cancer, are of limited efﬁcacy against 
androgen-independent, metastatic disease. Primary 
prevention appears as an attractive strategy to 
eradicate prostate cancer. Chemoprevention is a 
prophylactic method using non-toxic natural or 
synthetic compounds that reverse, inhibit, or 
prevent the development of cancer by inhibiting 
speciﬁc molecular steps in the carcinogenic 
pathway. Curcumin (Cur) is a promising 
chemopreventive compound (14). Cur (1,7-bis (4-
hydroxy-3-methoxy-phenyl)-1,6-hep-tadiene-3,5-
dione;diferuloylmethane) is a natural, yellow 
compound found in Curcuma longa that is regarded 
as a natural polyphenolic antioxidant presented in 
many kinds of herbs (15). This natural compound 
used as curry ingredient and is used since centuries 
in Ayurvedic, Chinese, and Hindu medicine 
systems as a potent anti-inﬂammatory agent. Cur 
has been showed various pharmacological activities 
including anticancer, anti-inflammatory, 
antioxidant, antimicrobial and anti-rheumatic 
effects (16). Particularly, Cur has been 
demonstrated efficacy as an antineoplastic factor 
for many types of malignancies, including prostate, 
gastric, colorectal, breast, lung  and pancreatic 
carcinoma (17). Despite of the well-received 
pharmacological properties, the therapeutic 
application of Cur has been hampered due to its 
deficits such as low aqueous solubility at acidic and 
physiological pH and its degradability in alkaline 
conditions. Moreover, poor absorption and rapid 
metabolism of Cur severely limit its bioavailability 
(18, 19). As a result, researchers have been 
exploring new strategies for the effective delivery 
www.thecancerpress.com 
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of Cur with novel formulations including 
liposomes, micelles, conjugates, nanoparticles, 
nanoglobules, solid dispersions, polymeric 
nanoparticles and micelles (20, 21). Recent 
advances of nanotechnology have generated many 
promising drug delivery systems. Niosomes are 
nonionic surfactant vesicles with a bilayer structure, 
which have been used to deliver various drug 
elements such as chemotherapeutic agents, genes, 
hormones, antigens, and peptides (16, 17). 
Niosomes have some similarities with liposomes 
but are composed of nonionic surfactants such as 
polyoxyethylene sorbitan monostearate (Tween 60), 
sorbitan monooleate (Span 80), sorbitane 
monostearate (Span 60) and 
polyoxyethylenesorbitan monooleate (Tween 80), 
instead of phospholipids utilized in liposomes. This 
vesicular carrier system provides protection of the 
drug from degradation and inactivation caused by 
immunological and pharmacological effects. 
Furthermore, niosomes surpass liposomes through 
low production cost and room-temperature 
chemical storage requirements. In recent years, 
niosomes are becoming increasingly accepted as an 
alternative method of drug delivery to liposomes, 
particularly for drugs with poor stability, low 
solubility, or rapid degradation (22-24). The present 
study investigated to effectively deliver Cur to 
tumor cells using niosomes composed of nonionic 
surfactants polyoxyethylene sorbitan monostearate 
and cholesterol, in order to improve the solubility 
and the therapeutic effects of Cur. The synthesis of  
Cur -loaded niosomes (Nio -Cur) and the 
physicochemical properties in terms of particle size, 
zeta potential, and polydispersity index (PDI) were 
evaluated. Moreover, the in vitro cytotoxicity of 
free curcumin and Nio -Cur against human prostate 
cancer cell line (PC-3) was investigated. 
Materials and Methods 
Materials  
Polyoxyethylene sorbitan monostearate, cholesterol 
and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl  tetrazolium bromide) were purchased 
from Sigma Chemical Co (St Louis, MO, USA). 
Curcumin was obtained from Sigma. Dialysis bags 
(MWCO 12000-14000) were supplied by 
Jingkehongda Biotechnology Co., Ltd. (Beijing, 
China). DMEM medium was purchased from 
InoClon Company, Iran. Chloroform, methanol and 
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other chemicals utilized in this study were 
analytical grade. PC-3 cell line was supplied from 
the Iranian Biological Resource Center (Tehran, 
Iran). 
Preparation of niosome and encapsulation 
efficiency of Cur by the thin film hydration 
method  
The thin film hydration method employed to 
prepare niosome (25). Polyoxyethylene sorbitan 
monostearate and cholesterol (80:20 molar ratios) 
were dissolved in chloroform. Then 0.5 mg.mL-1 
Cur was added and the mixture was warmed to 50 
ºC for 40 min. In continuation, solvent phase was 
evaporated on rotary evaporator until a thin-layered 
film formed. The thin film was hydrated with 
3000µl phosphate buffer saline. In order to decrease 
niosomal particle size, the resultant suspensions 
were sonicated (model UP200St, Hielscher 
Ultrasonics GmbH, Germany) at 60 HTz and 4 ºC 
for 20 min. Afterwards, free Cur (unloaded) was 
separated from niosomal Cur (Nio -Cur) by dialysis 
bags that had a cut-off of 12 kDa. 
Size and polydispersity index determination of 
Nanoparticles  
The  particle  size  distribution  and  polydispersity  
index  (PDI)  of  the  niosome  particles  was 
determined by dynamic light scattering  (DLS) 
using a ZetaPALS zeta potential and particle size 
analyzer (Brookhaven Instruments, Holtsville, NY, 
USA).  
Analysis of encapsulation efficiency 
In order to evaluate the entrapment eﬃciency, 
spectroscopic measurements were performed. The 
Nio -Cur particles were lysed with isopropanol to 
analyze Cur concentration. The amounts of Cur in 
niosome formulation were analyzed with a UV 
spectrophotometer (model T80+, PG Instruments, 
United Kingdom) at 429 nm (ʎmax) (26). 
Cell lines and culture conditions 
PC-3 cells were cultured  in DMEM medium  
supplemented with 10% fetal bovine serum (FBS), 
and penicillin/streptomycin (1 mg/mL) at  37°C  
and  5%  CO2  in  a  humidified  incubator. 
Cytotoxicity assays 
The cytotoxicity of niosomal formulations was 
determined by the MTT assay (27, 28). Briefly, PC-
3 cells were seeded in 96-well plates at 2×104 cells 
per well. Following attachment 24 hours, the cells 
were treated with 200 μl fresh medium containing 
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serial dilutions of free- Cur solution and niosomal 
Cur. After incubation for 72 h, 20 μl MTT (5 
mg.ml-1 in PBS) was added into each 96- well plate 
and incubated for three hour at 37 ˚C. Finally, the 
medium was carefully removed and 150 μl of 
DMSO was added to the each well to dissolve the 
formazan crystals formed. Absorbance of each well 
was recorded by EPOCH Microplate 
Spectrophotometer (synergy HTX, BioTek, USA) 
at 570 nm. The cytotoxicity of the diﬀerent 
formulations was expressed as the Inhibitory 
Concentration (IC50) value defined as the drug 
concentration required inhibiting cell growth by 
50% relative to the control. The IC50 values of free 
Cur and Nio -Cur were calculated using GraphPad 
Prism software. 
Statistical analysis 
Statistical data analyses were performed via 
GraphPad Prism software and expressed as mean ± 
SD. The student t-test was used when comparing 
two independent groups. P-Value < 0.05 was 
considered significant. 
Results    
Characterization of niosome formulation  
The PDI, mean size diameter and zeta potentials of 
niosomal Cur nanoparticles prepared with 
Polyoxyethylene sorbitan monostearate and 
cholesterol were found to be 0.247 ± 0.028, 127.5 
± 1.2 nm and -6 ± 0.21, respectively. 
Encapsulation efficiency 
 Encapsulation efficiency of formulation was 
determined through Cur standard curve in 
isopropanol (Fig. 1). Percent encapsulation of Cur 
in niosome nanoparticles was determined to be 
98.4 ± 0.4 %  
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Fig. 1. Curcumin standard curve in isopropanol   
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Evaluation of cellular cytotoxicity effect 
It was observed that toxicity of Cur in niosome 
formulation prepared with Polyoxyethylene 
sorbitan monostearate and cholesterol was higher 
than toxicity of free Cur. Furthermore, determined 
IC50 for niosome formulation was 46.37 μg/ml, 
while the IC50 for free drug was determined to be 
60.28 μg/ml (Fig. 2 and Fig. 3, respectively). The 
results showed that the Nio -Cur formula displayed 
significantly greater cytotoxic activity on PC-3 
prostate cancer cell line in comparison to free Cur.  
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Fig. 2. Cell viability assay of PC-3 cell line after 72 hours of treatment with various concentrations of entrapped curcumin.  




In the past few decades, considerable attention has 
been performed to the development of a novel drug 
delivery system. The aim of novel drug delivery 
systems is that it supplies the drug at a rate directed 
by the needs of the body, over the period of 
treatment, and it carries the drug directly to the 
tissues. Conventional delivery systems are unable 
to meet none of these. Novel drug delivery system 
sustains drug action at a predetermined rate, 
efficient drug level in the body and simultaneously 
minimizes the unpleasant side effects. It can also 
localize drug action in the diseased tissue by 
targeted drug delivery using carriers or chemical 
derivatization. It is specified that approximately 
40% of the identified chemistry compounds such as 
Cur are poorly water soluble, and this is a 
challenging issue in their formulation (6). Usage of 
drug delivery systems is a well-known method to 
improve the solubility and retain the 
pharmacological activity of such drugs (29). 
Different types of pharmaceutical carriers such as 
polymeric micelles, particulate systems, and macro- 
and micromolecules are introduced in the form of 
novel drug delivery system for drug delivery 
(30,31). Particularly, vesicular systems are drawing 
attention in this area, such as liposomes, niosomes, 
transferosomes and pharmacosomes. Among these 
drug delivery systems, niosomes have gained 
considerable importance. The disadvantages of 
liposomes such as  necessity of an inert atmosphere 
during production, changeable  phospholipid purity 
and high production cost can be eliminated by 
niosomes (29). Niosomes have several advantages 
such as high patient compliance, accommodate 
drug molecules with a wide range of solubilities, 
variable and controllable characteristics, controlled 
drug release, increasing the stability of 
encapsulated drug, improving oral bioavailability of 
poorly absorbed agents, enhancing skin penetration 
of drugs, and reaching the site of action by oral, 
parenteral and topical routes (32-34). In this study, 
a poorly water-soluble anticancer agent Cur was 
chosen as a model drug to be encapsulated in 
niosomes to examine the effects of niosome 
components on Cur properties. Nanoparticles 
average diameter, size distribution and zeta 
potential were obtained. The thin film hydration 
method used in this study to prepare niosomes was 
easy, appropriate encapsulation efficiency and low 
cost benefit. Measurement results in nanoniosomal 
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Cur affirmed the particle size in nano scale. 
Karewicz et al. (35) prepared  Cur -encapsulated 
liposomes consisting of dihexyl phosphate (DPH), 
egg yolk phosphatidylcholine (EYPC) and 
cholesterol by the film evaporation technique, 
allowing Cur to be soluble in the lipophilic bilayer 
owing to its lipophilicity. EYPC/DPH/cholesterol 
liposomal bilayer enabled improving the stability of 
Cur and served as a favorable vehicle for  Cur. Xu 
et al. (32) prepared curcumin-encapsulated niosome 
containing span 80, tween 80, and poloxamer 188 
by the film evaporation technique. This system 
provided controlled release of curcumin, thereby 
improving its therapeutic capability. The results of 
studying encapsulation efficiency showed that 
amount of Cur entrapped in nanoniosome 
formulation was very high. Sonication processes 
not only reduced the size of particles, but also 
caused particles to be more homogeneous by 
reducing the size distribution. Considering the 
competencies of niosome overwhelming liposome, 
we prepared a niosome-based system for Cur 
delivery to improve its cytotoxic efficacy. Nio -Cur 
showed enhanced cytotoxicity effect when 
compared to free curcumin treatment of the PC-3 
cancer cell line, indicating that niosomes promoted 
cellular uptake and the protection of the bioactive, 
but biochemically unstable chemical, curcumin. Xu 
et al. (32)prepared a niosome containing curcumin 
and evaluated its cytotoxicity effects on ovarian 
cancer A2780 cells. They found Nio -Cur exhibited 
enhanced cytotoxic activity and apoptotic rate 
against ovarian cancer A2780 cells compared with 
freely dispersed Cur. 
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Conclusion 
In this study, a novel  Cur -loaded niosome system was developed to effectively deliver Cur for the treatment 
of prostate cancer. It was demonstrated that niosomes provided a high entrapment efficiency of Cur. The results 
of study affirmed the positive effect of sonication process to prepare the smaller particles. The results indicated 
that most of the drug is encapsulated into the carrier. Moreover, Nio -Cur exhibited enhanced cellular cytotoxic 
activity against prostate cancer PC-3 cells. According these results, the prepared Nio -Cur indicated to be 
promising as a nano-size carrier for the delivery of Cur and prostate cancer therapy. 
